The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken
Crossref DOI link: https://doi.org/10.1007/s00330-014-3458-5
Published Online: 2014-10-31
Published Print: 2015-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hillengass, J.
Stoll, J.
Zechmann, C. M.
Kunz, C.
Wagner, B.
Heiss, C.
Sumkauskaite, M.
Moehler, T. M.
Schlemmer, H. P.
Goldschmidt, H.
Delorme, S.
Text and Data Mining valid from 2014-10-31